cavion llc logo

Cavion LLC.

Transforming lives through first-in-class therapies for oncology and neurology. Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3).

In Apr 2014, Tau Therapeutics LLC merged with Xdynia LLC to form Cavion LLC, a multi-asset platform company built around T-type calcium channel blockade in both oncologic and neurologic diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://cavionpharma.com
Founded2014
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
600 East Water Street, Suite E, VA 22902
Charlottesville
United States
Email
Contact Number
+1 434 200 8442

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cavion” connections=”true” suffix=””]

Cavion relys on its Interlaced Therapy_, which capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. Interlaced Therapy_ magnifies the cancer fighting effects of standard chemotherapies, thereby making chemotherapy more effective.

In Nov 2015, Cavion raised $5 Mn through private placement of convertible notes with new and existing investors. Cavion has raised over $18 Mn from private investors throughout the United States and received over $15 Mn in non-dilutive resources.

In Jan 2017, Cavion received $26.1Mn in venture fuding which was co-led by Lilly Ventures and Novartis Venture Fund along ei Enso Ventures